At a glance
A hormone with peripheral actions and context-dependent brain signaling.
This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.
How it works
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
Established obstetric contexts and exploratory social-behavior studies address different questions. A behavioral association does not establish a broadly effective treatment.[2][8][9]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of Oxytocin.
Source-reported adverse effects and cautions
Published human trials of oxytocin have reported a placebo‑like safety profile at doses roughly equivalent to 18–40 IU intranasally per administration (approximately 30–67 mcg)[8]. Daily cumulative doses in research are often in the tens to low hundreds of micrograms. For example, an 8‑week trial in adults used 96 IU per day intranasally (24 IU four times daily) with no serious adverse events[3]. A systematic review noted no reliable side effects with short‑term oxytocin in the 18–40 IU range, and even higher daily exposures (approximately 96 IU or approximately 160 mcg) did not differ from placebo in adverse event frequency[8].
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 5 mg · 1 source tables
Standard / Gradual Approach (3 mL = ~1.67 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 100 mcg | 6 units (0.06 mL) |
| Weeks 3–4 | 200 mcg | 12 units (0.12 mL) |
| Weeks 5–6 | 300 mcg | 18 units (0.18 mL) |
| Weeks 7–8 | 400 mcg | 24 units (0.24 mL) |
| Weeks 9–12 | 500 mcg | 30 units (0.30 mL) |
Frequency: Inject once daily subcutaneously. This schedule uses the standard 3.0 mL dilution for practical unit measurements on insulin syringes. For ≤10‑unit (≤0.10 mL) administrations, consider 30‑ or 50‑unit insulin syringes for improved readability.
Additional schedule context & duration
Concise summary of the once‑daily regimen.
- Goal: Explore oxytocin’s effects on social bonding, stress reduction, metabolic function, and pain modulation[1][2].
- Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
- Dose Range: 100–500 mcg daily with gradual titration.
- Reconstitution: 3.0 mL per 5 mg vial (~1.67 mg/mL) for accurate unit measurements.
- Storage: Lyophilized frozen or refrigerated; reconstituted refrigerated for up to 28–30 days; avoid repeated freeze–thaw cycles.
Suggested daily titration approach based on published research protocols[3][4].
- Start: 100 mcg daily for 2 weeks; increase to 200 mcg for weeks 3–4.
- Titration: Increase by ~100 mcg every 2 weeks as tolerated (300 mcg weeks 5–6, 400 mcg weeks 7–8).
- Target: 500 mcg daily by weeks 9–12 (typical upper limit for research protocols).
- Frequency: Once per day (subcutaneous); rotate injection sites.
- Cycle Length: 8–12 weeks; optional extension to 16 weeks.
- Timing: Any consistent time; oxytocin has rapid clearance, so effects are acute per dose.
Preparation
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Storage Instructions
Proper storage preserves peptide quality[13][14].
- Lyophilized: Store at −20 °C (−4 °F) or lower for long‑term storage; refrigerate at 2–8 °C (35.6–46.4 °F) for shorter periods. Protect from light and moisture.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); stable for up to 28–30 days with bacteriostatic water. Mark date of reconstitution and discard after 4 weeks.
- Extended Storage: Can aliquot reconstituted solution into sterile vials and freeze at −20 °C (−4 °F). Do not subject to repeated freeze–thaw cycles; thaw each aliquot only once.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Injection Technique
Proper subcutaneous injection technique is critical for consistent dosing and safety[11][12].
- Supplies: A U‑100 insulin syringe (1 mL, 100 units) with a fine‑gauge needle (e.g., 29–31 G), alcohol swabs, and a sharps disposal container.
- Site Selection: Choose a site with a layer of subcutaneous fat. Common SC injection areas include the abdomen (avoiding 1–2 inches around the navel), outer upper arms, thighs, or buttocks. Rotate injection sites systematically; do not inject into the same spot repeatedly—maintain at least approximately 1.5 inch spacing from the last site.
- Injection Steps: Clean the chosen site with an alcohol pad and let dry. Using one hand, pinch a fold of skin between your thumb and forefinger to elevate the subcutaneous layer. Hold the syringe like a pencil or dart and insert the needle at a 45°–90° angle into the pinched skin fold (for most, a 90° angle is fine; a 45° angle may be used if limited subcutaneous depth). Insert the needle fully into the subcutaneous tissue. Slowly depress the plunger to inject the oxytocin solution. After the full dose is delivered, withdraw the needle at the same angle. If slight bleeding occurs, gently press an alcohol swab on the site (do not rub vigorously). Dispose of the used syringe and needle immediately in a puncture‑proof sharps container.
- Technique Tips: Injecting subcutaneously should be relatively painless with a fine needle; inserting quickly through the skin can minimize discomfort. Always use a new sterile needle/syringe for each injection. Ensure no air bubbles in the syringe to improve accuracy. If the volume is very small (less than 0.1 mL), be extra careful to expel any air and inject slowly, as low volumes are harder to measure precisely.
Materials & quantity planning
Source materials checklist · 5 mg
Plan based on an 8–16 week daily protocol with gradual titration.
-
Peptide Vials (Oxytocin, 5 mg each):
- 8 weeks ≈ 3 vials
- 12 weeks ≈ 6 vials
- 16 weeks ≈ 9 vials
-
Insulin Syringes (U‑100):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
-
Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- 8 weeks (3 vials): 9 mL → 1 × 10 mL bottle
- 12 weeks (6 vials): 18 mL → 2 × 10 mL bottles
- 16 weeks (9 vials): 27 mL → 3 × 10 mL bottles
-
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100‑count boxes
- 12 weeks: 168 swabs → recommend 2 × 100‑count boxes
- 16 weeks: 224 swabs → recommend 3 × 100‑count boxes
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 5 mg per vial and 3 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 03
Research publication
PubMed — Intranasal Oxytocin for Obesity (8‑week trial using 96 IU per day in adults) (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 06
Source document
Science Direct — The physiology and pharmacology of oxytocin in labor and in the puerperium (opens in a new tab)www.sciencedirect.com
Back to overview ↑ - 07
Research publication
PubMed — Subcutaneous Oxytocin Injection Reduces Heat Pain: A Randomized‑Controlled Trial (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 08
Research publication
PubMed — A review of safety, side‑effects and subjective reactions to intranasal oxytocin in human research (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 09
Research publication
PubMed — The effects of oxytocin on eating behaviour and metabolism in humans (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 10
Research publication
PMC — Oxytocin: A Potential Therapeutic for Obesity (review of oxytocin’s metabolic effects) (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 11
Source document
Johns Hopkins Arthritis Center — How to give a subcutaneous injection (step‑by‑step technique guide) (opens in a new tab)www.hopkinsarthritis.org
Back to overview ↑ - 14
Public health resource
FDA Accessdata — Chemistry Review Document (oxytocin drug chemistry and stability information) (opens in a new tab)www.accessdata.fda.gov
Back to overview ↑
Continue exploring
Related topics are not interchangeable compounds or formulations.